Abstract | BACKGROUND: OBJECTIVES: METHODS: MAIN OUTCOME MEASURE: Reduction of skin fibrosis and increase in joint mobility evaluated by the modified Rodnan skin score and a goniometer. RESULTS: In two patients, the imatinib mesylate dose was reduced to 200 mg/day and in one patient to 100 mg/day. Two patients were treated for 24 weeks, one patient for 16 weeks and one patient for 4 weeks. Three patients experienced tethering of their skin which lessened with reduction in modified Rodnan skin score from 24 to 20, 24 to 17 and 21 to 14 but with very limited changes in joint mobility. The fourth patient discontinued the treatment due to a complicating infection. CONCLUSION:
Imatinib mesylate may be an effective drug in the treatment of skin fibrosis in moderate to severe NSF cases, even at reduced doses. We found a positive clinical effect on the skin, but no convincing improvement of the joint mobility. Only few patients could be recruited limiting the interpretation and conclusions of the results.
|
Authors | T R Elmholdt, N H Buus, M Ramsing, A B Olesen |
Journal | Journal of the European Academy of Dermatology and Venereology : JEADV
(J Eur Acad Dermatol Venereol)
Vol. 27
Issue 6
Pg. 779-84
(Jun 2013)
ISSN: 1468-3083 [Electronic] England |
PMID | 22188390
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology. |
Chemical References |
- Benzamides
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines
- Imatinib Mesylate
|
Topics |
- Adult
- Benzamides
(administration & dosage)
- Female
- Humans
- Imatinib Mesylate
- Male
- Middle Aged
- Nephrogenic Fibrosing Dermopathy
(drug therapy)
- Piperazines
(administration & dosage)
- Protein Kinase Inhibitors
(administration & dosage)
- Pyrimidines
(administration & dosage)
- Severity of Illness Index
|